A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

By Chow Laura   Eckhardt S.   O’Bryant Cindy   Schultz Mary   Morrow Mark   Grolnic Stacy   Basche Michele   Gore Lia  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 4, 2008-09 ,pp. : 631-646

Springer Publishing Company

Access to resources Recommend Favorite

Farnesyl Transferase Inhibitors

By Li Tianhong   Sparano Joseph  

Cancer Investigation, Vol. 26, Iss. 7, 2008-08 ,pp. : 653-661

Informa Healthcare

Access to resources Recommend Favorite

Tamoxifen and the Farnesyl Transferase Inhibitor FTI-277 Synergize to Inhibit Growth in Estrogen Receptor-Positive Breast Tumor Cell Lines

By Ellis C.A.  

Breast Cancer Research and Treatment, Vol. 78, Iss. 1, 2003-03 ,pp. : 59-67

Springer Publishing Company

Access to resources Recommend Favorite

Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma

By Andreopoulou Eleni   Vigoda Ivette   Valero Vicente   Hershman Dawn   Raptis George   Vahdat Linda   Han Hyo   Wright John   Pellegrino Christine   Cristofanilli Massimo   Alvarez Ricardo   Fehn Karen   Fineberg Susan   Sparano Joseph  

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 429-435

Springer Publishing Company

Access to resources Recommend Favorite

Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue

By Tahir S.K.   Gu W.-Z.   Zhang H.-C.   Leal J.   Lee J.Y.   Kovar P.   Saeed B.   Cherian S.P.   Devine E.   Cohen J.   Warner R.   Wang Y.-C.   Stout D.   Arendsen D.L.   Rosenberg S.   Ng S.-C.  

European Journal of Cancer, Vol. 36, Iss. 9, 2000-06 ,pp. : 1161-1170

Elsevier

Access to resources Recommend Favorite